Showing results (31-40 of 731) with videos related to
Sort By:
Pageof 74
Cancer Research|September 25, 2012
Intratumor heterogeneity: evolution through space and timeCharles SwantonThe Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.Journal for Immunotherapy of Cancer|July 17, 2021
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsBenjamin Switzer, John Haanen, Paul C Lorigan, et al.Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.ESMO Open|August 20, 2019
How we treat neurological toxicity from immune checkpoint inhibitorsLavinia Spain, Zayd Tippu, James M Larkin, et al.The Journal of Pathology|April 27, 2013
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanomaSimon J Furney, Samra Turajlic, Gordon Stamp, et al.Nature Reviews. Disease Primers|March 10, 2017
Renal cell carcinomaJames J Hsieh, Mark P Purdue, Sabina Signoretti, et al.Journal of Neurology, Neurosurgery, and Psychiatry|July 17, 2025
Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologistMark D Willis, Ben Schroeder, Laura Marandino, et al.Cancer Cell|January 14, 2015
Biological and therapeutic impact of intratumor heterogeneity in cancer evolutionNicholas McGranahan, Charles SwantonCancer Research|February 15, 2023
Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder CancerDeborah Caswell, Charles SwantonPageof 74